285 related articles for article (PubMed ID: 30726546)
1. Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.
Madurantakam Royam M; Kumarasamy C; Baxi S; Gupta A; Ramesh N; Kodiveri Muthukaliannan G; Jayaraj R
Mol Diagn Ther; 2019 Feb; 23(1):65-82. PubMed ID: 30726546
[TBL] [Abstract][Full Text] [Related]
2. Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis.
Jayaraj R; Nayagam SG; Kar A; Sathyakumar S; Mohammed H; Smiti M; Sabarimurugan S; Kumarasamy C; Priyadharshini T; Gothandam KM; Ramesh N; Gupta A; Baxi S; Swamiappan S; Krishnan S
Cells; 2019 Oct; 8(10):. PubMed ID: 31615089
[TBL] [Abstract][Full Text] [Related]
3. Clinical Investigation of Chemotherapeutic Resistance and miRNA Expressions in Head and Neck Cancers: A Thorough PRISMA Compliant Systematic Review and Comprehensive Meta-Analysis.
Jayaraj R; Polpaya K; Kunale M; Kodiveri Muthukaliannan G; Shetty S; Baxi S; Mani RR; Paranjothy C; Purushothaman V; Kayarohanam S; Janakiraman AK; Balaraman AK
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553594
[No Abstract] [Full Text] [Related]
4. Molecular Investigation of miRNA Biomarkers as Chemoresistance Regulators in Melanoma: A Protocol for Systematic Review and Meta-Analysis.
Shaw P; Raymond G; Tzou KS; Baxi S; Mani RR; Kumar Govind S; Chandramoorthy HC; Sivanandy P; Rajagopal M; Samiappan S; Krishnan S; Jayaraj R
Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052456
[TBL] [Abstract][Full Text] [Related]
5. Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis.
Jayaraj R; Raymond G; Krishnan S; Tzou KS; Baxi S; Ram MR; Govind SK; Chandramoorthy HC; Abu-Khzam FN; Shaw P
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397507
[No Abstract] [Full Text] [Related]
6. MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication.
Moradi Marjaneh R; Khazaei M; Ferns GA; Avan A; Aghaee-Bakhtiari SH
IUBMB Life; 2019 Oct; 71(10):1428-1441. PubMed ID: 31322820
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs and colorectal cancer chemoresistance: New solution for old problem.
Vaghari-Tabari M; Majidinia M; Moein S; Qujeq D; Asemi Z; Alemi F; Mohamadzadeh R; Targhazeh N; Safa A; Yousefi B
Life Sci; 2020 Oct; 259():118255. PubMed ID: 32818543
[TBL] [Abstract][Full Text] [Related]
8. The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms.
Marjaneh RM; Khazaei M; Ferns GA; Avan A; Aghaee-Bakhtiari SH
J Cell Physiol; 2019 Mar; 234(3):2306-2316. PubMed ID: 30191973
[TBL] [Abstract][Full Text] [Related]
9. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
10. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Hu J; Cai G; Xu Y; Cai S
Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
[TBL] [Abstract][Full Text] [Related]
11. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
[TBL] [Abstract][Full Text] [Related]
12. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of noncoding RNAs in colorectal cancer chemoresistance.
Wei L; Wang X; Lv L; Zheng Y; Zhang N; Yang M
Cell Oncol (Dordr); 2019 Dec; 42(6):757-768. PubMed ID: 31359293
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.
Sabarimurugan S; Madhav MR; Kumarasamy C; Gupta A; Baxi S; Krishnan S; Jayaraj R
Mol Diagn Ther; 2020 Feb; 24(1):15-30. PubMed ID: 32020560
[TBL] [Abstract][Full Text] [Related]
15. Predictive power of circulating miRNAs in detecting colorectal cancer.
Zeng W; Tu Y; Zhu Y; Wang Z; Li C; Lao L; Wu G
Tumour Biol; 2015 Apr; 36(4):2559-67. PubMed ID: 25527153
[TBL] [Abstract][Full Text] [Related]
16. The expression and clinical significance of microRNAs in colorectal cancer detecting.
Yang X; Zhong J; Ji Y; Li J; Jian Y; Zhang J; Yang W
Tumour Biol; 2015 Apr; 36(4):2675-84. PubMed ID: 25480414
[TBL] [Abstract][Full Text] [Related]
17. Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer.
Choi TG; Nguyen MN; Kim J; Jo YH; Jang M; Nguyen NNY; Yun HR; Choe W; Kang I; Ha J; Tang DG; Kim SS
J Pathol; 2018 Sep; 246(1):115-126. PubMed ID: 29876924
[TBL] [Abstract][Full Text] [Related]
18. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis.
Carter JV; Galbraith NJ; Yang D; Burton JF; Walker SP; Galandiuk S
Br J Cancer; 2017 Mar; 116(6):762-774. PubMed ID: 28152545
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
20. The role of circulating microRNAs as novel biomarkers in diagnosing colorectal cancer: a meta-analysis.
Rokkas T; Kothonas F; Rokka A; Koukoulis G; Symvoulakis E
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):819-25. PubMed ID: 25856691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
